Imprimis, SightLife Surgical enter sales and marketing agreement for Serum Tears
Click Here to Manage Email Alerts
Imprimis Pharmaceuticals and SightLife Surgical have signed a strategic sales and marketing agreement for Imprimis’ Serum Tears for chronic dry eye, according to a press release.
SightLife’s sales team will offer Serum Tears to physicians, large practice groups, surgery centers, hospitals and health care organizations under the agreement, the release said.
“This partnership with Imprimis uniquely positions us to help the thousands of domestic physicians treating dry eye and makes this important product widely available to patients in need of these drops across the country,” Monty Montoya, president and CEO of SightLife, said in the release.
Serum Tears autologous serum eye drops are for chronic dry eye patients who do not respond to traditional dry eye treatments. The product can also be used as a preventive treatment of a transplant for patients with corneal epithelial defects, the release said.
“Partnering with SightLife Surgical represents an important step in our strategic plan to efficiently expand our sales presence and increase our growing customer base,” Mark L. Baum, CEO of Imprimis, said in the release.